This Week’s Data Dump May Lead To More Stock Market Pain

This column is my opinion and expresses my views. Those views can change at a moments notice when the market changes. I am not right all the time and I do not expect to be. I disclose all my positions clearly listed on the page, and I do not trade my account on the stocks spoken of in this column unless fully disclosed. If that does not work for you stop reading and close the page. Do not bother me or harass me.

Otherwise, enjoy the column!

Subscribe to The Market Chronicle to get the Daily Monster Market Commentary and join the 2,893 subscribers getting it for FREE!


#Stocks – $ARKK, $IWM, $XBI

#Macro – $SPX, #RATES, $DXY

Mike’s Reading The Markets Macro Subscription Service on Seeking Alpha

Some Recent Titles:



If you are taking a vacation this week, you chose the wrong week. From Tuesday until Friday, there will be a massive data dump. Starting Tuesday, we get the Employment Cost Index and Home Prices. On Wednesday, we get ADP, JOLTS, ISM manufacturing, and the Fed. Thursday, Unit Labor costs, non-farm productivity, initial jobless claims, and durable goods. On Friday, the jobs report and the ISM services.

This is the type of data that is not going only to move the markets but also set the tone and the dialogue for fourth-quarter GDP growth. This means the dollar and rates will be more volatile, and the equity market will be trading off dollar and rate changes.

Subscribe to the The Market Chronicle to get it Daily and join the 2,893 subscribers getting it for FREE!


The dollar looks like it wants to go higher from here based on what appears to be a bull flag that has formed. That pattern in the dollar could be setting up for a considerable move higher back towards 109.50 on the dollar index. The data that comes this week will need to support that narrative, and the Fed messaging will, too. However, based on how the dollar appears to be setting up heading into this week, it seems the dollar may get the hot data and hawkish Fed.


Similar patterns are present in the euro with what appears to be a bear flag, which makes sense given the euro’s weighting in the dollar index. This bearish pattern in the euro suggests a drop back to around 1.03.


Meanwhile, we are seeing the 10-year also consolidate around the 5% level and appear to be forming a bull flag, too, which is suggestive of a 10-year rate that is also likely to move higher and see a move perhaps to that 5.25% level.

It isn’t that we are only seeing higher rates, but we are finally witnessing spreads widen as investors reassess the rates they are getting paid for the amount of risk they are taking. This is happening not just in the US but in Europe, too, with German and Italian sovereign spreads widening, which has resulted in high-yield spreads here in the US widening, too.

Widening spreads in the US  have led to rising levels of implied volatility for the equity market and higher earning yields, which have led to lower equity prices. What is pushing equities lower is not only higher rates but the repricing of risk due to those higher rates. The market seemed to think that rates would stay low, and because, in the market’s view, rates would remain low, there was no reason to reprice risk. But that has all changed.

So, as long as rates and the dollar continue to climb, the repricing of risk shall likely continue becuase it doesn’t seem that, at the current level, stocks are correctly priced given bond yields. The SPY to IEF ratio shows that stocks will likely underperform relative to bonds over the short term.

Biotech (XBI)

For the biotech ETF (XBI) has fallen back to levels seen in 2017, 2018, 2020, and 2022. The sad thing for this group is that it may not be finished falling, either. If the XBI should break support around $64, the next level of support comes at gap fills from 2016 at $54 and $57.

Russell 2000 (IWM)

When biotech underperforms, small-cap underperforms, which has the IWM back to its 2022 lows. You can see how ominous the triple top in the IWM looks and what a break of the neckline at $162.50 could mean for the IWM, with gaps to fill down around $127. 


This is more broadly a sign of long-duration growth assets doing poorly, which is also why the ARKK ETF is trading back near its low and a level seen back in 2017.

Magnificent 7

This is probably why the Mag 7, when added into one entity, has the same look as the SPY to IEF and the QQQ to IEF ratio. They are telling us the same thing. Stocks are repricing for a higher rate world, and the higher rates go, the more stocks will need to reprice. So, if you are trying to understand when stocks will stop falling, turn your attention to the macro data, bonds, and the dollar. They will tell you when stocks have finished falling before stocks will tell you when they are finished falling.


Charts used with the permission of Bloomberg Finance L.P. This report contains independent commentary to be used for informational and educational purposes only. Michael Kramer is a member and investment adviser representative with Mott Capital Management. Mr. Kramer is not affiliated with this company and does not serve on the board of any related company that issued this stock. All opinions and analyses presented by Michael Kramer in this analysis or market report are solely Michael Kramer’s views. Readers should not treat any opinion, viewpoint, or prediction expressed by Michael Kramer as a specific solicitation or recommendation to buy or sell a particular security or follow a particular strategy. Michael Kramer’s analyses are based upon information and independent research that he considers reliable, but neither Michael Kramer nor Mott Capital Management guarantees its completeness or accuracy, and it should not be relied upon as such. Michael Kramer is not under any obligation to update or correct any information presented in his analyses. Mr. Kramer’s statements, guidance, and opinions are subject to change without notice. Past performance is not indicative of future results. Neither Michael Kramer nor Mott Capital Management guarantees any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment commentary presented in this analysis. Strategies or investments discussed may fluctuate in price or value. Investments or strategies mentioned in this analysis may not be suitable for you. This material does not consider your particular investment objectives, financial situation, or needs and is not intended as a recommendation appropriate for you. You must make an independent decision regarding investments or strategies in this analysis. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Before acting on information in this analysis, you should consider whether it is suitable for your circumstances and strongly consider seeking advice from your own financial or investment adviser to determine the suitability of any investment.

Thanks For Visiting The Market Chronicle!

Sign up to receive more great market content like what you just read sent to your inbox daily!

We don’t spam! Read our privacy policy for more info.